NYSE LISTED TEST STOCK FOR CTS AND CQS
NYSE LISTED TEST STOCK FOR CTS AND CQS
NYSE LISTED TEST STOCK FOR CTS AND CQS (CBO) - Net Assets
Latest net assets as of June 2021: $3.44 Billion USD
Based on the latest financial reports, NYSE LISTED TEST STOCK FOR CTS AND CQS (CBO) has net assets worth $3.44 Billion USD as of June 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.10 Billion) and total liabilities ($3.65 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.44 Billion |
| % of Total Assets | 48.51% |
| Annual Growth Rate | -0.2% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
NYSE LISTED TEST STOCK FOR CTS AND CQS - Net Assets Trend (2019–2020)
This chart illustrates how NYSE LISTED TEST STOCK FOR CTS AND CQS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NYSE LISTED TEST STOCK FOR CTS AND CQS (2019–2020)
The table below shows the annual net assets of NYSE LISTED TEST STOCK FOR CTS AND CQS from 2019 to 2020.
| Year | Net Assets | Change |
|---|---|---|
| 2020-12-31 | $3.35 Billion | -0.20% |
| 2019-12-31 | $3.36 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to NYSE LISTED TEST STOCK FOR CTS AND CQS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 19.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2020)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.81 Billion | 54.04% |
| Common Stock | $1.20 Million | 0.04% |
| Other Components | $1.54 Billion | 45.92% |
| Total Equity | $3.35 Billion | 100.00% |
NYSE LISTED TEST STOCK FOR CTS AND CQS Competitors by Market Cap
The table below lists competitors of NYSE LISTED TEST STOCK FOR CTS AND CQS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
IEMR Resources Inc
V:IRI
|
$237.77K |
|
PRESIDENT STUDIO S.A.
WAR:PRE
|
$237.85K |
|
GECCH
NASDAQ:GECCH
|
$237.99K |
|
ALL-P-J
NYSE:ALL-P-J
|
$238.02K |
|
CAE (CE9.SG)
STU:CE9
|
$237.62K |
|
MFA Financial, Inc. 8.875%
NYSE:MFAN
|
$237.58K |
|
Lodzia
TA:LODZ
|
$237.41K |
|
SIRIUS XM RADIO - Dusseldorf Stock Exchang
DU:RDO
|
$237.40K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NYSE LISTED TEST STOCK FOR CTS AND CQS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2019 to 2020, total equity changed from 3,355,600,000 to 3,348,900,000, a change of -6,700,000 (-0.2%).
- Net income of 468,200,000 contributed positively to equity growth.
- Dividend payments of 170,600,000 reduced retained earnings.
- Share repurchases of 348,900,000 reduced equity.
- Other factors increased equity by 44,600,000.
Equity Change Factors (2019 to 2020)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $468.20 Million | +13.98% |
| Dividends Paid | $170.60 Million | -5.09% |
| Share Repurchases | $348.90 Million | -10.42% |
| Other Changes | $44.60 Million | +1.33% |
| Total Change | $- | -0.20% |
Book Value vs Market Value Analysis
This analysis compares NYSE LISTED TEST STOCK FOR CTS AND CQS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.80x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $30.32 | $25.00 | x |
| 2020-12-31 | $31.21 | $25.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NYSE LISTED TEST STOCK FOR CTS AND CQS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.98%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.95x
- Recent ROE (13.98%) is above the historical average (12.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 11.17% | 0.00% | 0.00x | 1.52x | $39.34 Million |
| 2020 | 13.98% | 0.00% | 0.00x | 1.95x | $133.31 Million |
Industry Comparison
This section compares NYSE LISTED TEST STOCK FOR CTS AND CQS's net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $23,273,991,755
- Average return on equity (ROE) among peers: 33.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NYSE LISTED TEST STOCK FOR CTS AND CQS (CBO) | $3.44 Billion | 11.17% | 1.06x | $237.68K |
| Arçelik Anonim Sirketi (ACKAF) | $59.56 Billion | 12.87% | 3.33x | $19.95K |
| Argo Group US Inc. 6.5% SR NTS 42 (ARGD) | $1.23 Billion | -15.51% | 0.05x | $232.01K |
| American Crystal Sugar Company PFD REST NON DIV (ASCS) | $316.55 Million | 254.25% | 1.77x | $54.72 Million |
| Autobacs Seven Co. Ltd (ATBSF) | $127.35 Billion | 4.24% | 0.47x | $167.34K |
| Brookfield Asset Management Inc FR PRF PERPETUAL CAD 25 Ser 2 Cls A (BKFAF) | $11.77 Billion | 6.69% | 3.72x | $76.46K |
| Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) | $5.08 Billion | 14.69% | 0.67x | $9.45 Million |
| BOL Bancshares Inc. PFD (BOLBP) | $11.94 Million | 0.62% | 6.68x | $0.91 |
| Canadian Utilities Limited 2ND PFD SER Y (CNAUF) | $4.14 Billion | 10.45% | 1.28x | $142.90K |
| Central Parking Finance Trust PFD TR CV SECS (CRLKP) | $374.10 | 13.04% | 2.96x | $224.78K |